Podcast appearances and mentions of Rob Coleman

In the first episode of the second season of Light & Magic, George Lucas and Industrial Light & Magic take viewers behind the scenes of creating the special effects for The Phantom Menace.   In this fully armed and operational episode of Podcast Stardust, we discuss: Our overall thoughts and reactions to the first episode of the second season of Light & Magic, How everyone at Industrial LIght & Magic wanted to work on a Star Wars movie, A surprising movie and character that was instrumental to the development of other digital characters like Jar Jar Binks, How people such as Rob Coleman, John Knoll, and Doug Chiang contributed to ILM and The Phantom Menace, The team effort that went into creating Jar Jar Binks, The storyboards for The Phantom Menace, and The software behind the podrace. Thanks for joining us for another episode! Subscribe to Podcast Stardust for all your Star Wars news, reviews, and discussion wherever you get your podcasts. And please leave us a five star review on Apple Podcasts.   Find Jay and her cosplay adventures on J.Snips Cosplay on Instagram.   Join us for real time discussion on the RetroZap Discord Server here: RetroZap Discord. Follow us on social media: Twitter | Facebook | Instagram | Pinterest | YouTube. T-shirts, hoodies, stickers, masks, and posters are available on TeePublic. Find all episodes on RetroZap.com.

We love Light & Magic season 2 so let's talk about it! Join us as we discuss Joe Johnston's three-episode look at the evolution of ILM after Jurassic Park, through the prequel trilogy, and beyond, highlighted by its incredible people. We layer in some highlights from our time with Rob Coleman too! Please checkout our new site trbpodcasts.com for easy access to our podcasts and our brand new merch shop! If you like having a good time talking Star Wars, you've found a great spot! Join the Resistance, and be sure to join us live Wednesday night for the K-2S Show covering ANDOR season 2!

Join Caitlin and Charlotte on this journey listening and reacting to the Star Wars: Episode III REVENGE OF THE SITH audio commentary! We pick quotes from George Lucas, Rick McCallum (EP), Rob Coleman (animation director), John Knoll and Roger Guyett (Visual Effects Supervisor) to unpack. On this episode: How does George Lucas describe Anakin throughout the commentary?  What were the challenges with General Grievous and Yoda as animated characters?  How Rick McCallum talks about George Lucas's creative process.  Our thoughts of Anakin and Padmé's relationship in this latest viewing! (And what George thinks from a macro view!) …and so much more! Join our Patreon community and unlock bonus episodes + more! Our website! Follow us on Twitter/X @skytalkerspod Follow us on TikTok @skytalkers Follow us on Facebook Follow us on Instagram @skytalkerspodcast Follow Charlotte on Twitter/X @crerrity Follow Caitlin on Twitter/X @caitlinplesher Email us! hello@skytalkers.com Learn more about your ad choices. Visit megaphone.fm/adchoices

A broad conversation with Rob Coleman(check out Episode 56 ) about the current farming situation in Ireland and whats changed since we chatted last year.

From the archives, Bryan digs out an interview with Rob Coleman, the animation director of the Star Wars prequels to talk about The Phantom Menace after all these years and the reception it got in 1999 versus how its been received today.

Rob Coleman, senior vice president of sales now for both Holland America Line and Seabourn, talks with James Shillinglaw of Insider Travel Report, talks about how he will now oversee sales for both brands with one dedicated team. Coleman also is no stranger to Seabourn, having worked in charter sales and more for the luxury line, even though he's longtime sales executive and fan of Holland America. For more information, visit www.seabourn.com and www.hollandamerica.com. No time to watch this video? Listen to the audio podcast with the same title, available on Spotify, Pandora, Stitcher, PlayerFM, Listen Notes, Podchaser, TuneIn + Alexa, Podbean, iHeartRadio, Google,Amazon Music/Audible, Deezer, Podcast Addict, and iTunes Apple Podcasts, which supports Overcast, Pocket Cast, Castro and Castbox.

Rob Coleman, senior vice president of sales now for both Holland America Line and Seabourn, talks with James Shillinglaw of Insider Travel Report, talks about how he will now oversee sales for both brands with one dedicated team. Coleman also is no stranger to Seabourn, having worked in charter sales and more for the luxury line, even though he's longtime sales executive and fan of Holland America. For more information, visit www.seabourn.com and www.hollandamerica.com. If interested, the original video of this podcast can be found on the Insider Travel Report Youtube channel or by searching for the podcast's title on Youtube.

[School of Movies 2024] He's responsible for some of the most adored and industry-changing films of all time, and for some of the biggest cases of fan backlash ever recorded. It's maybe a little harder to remember now, after year upon year of Disney's Star Wars being declared the worst thing that has ever been put to screen, but a few years earlier, similar guys were saying similar things about the man that many fans wish had never sold to America's Mousy Spirit of Capitalism. What we have for you here is a focused collection of monologues drawn from commentaries across all six of the movies he was directly in charge of, bringing you from Star Wars in 1977 all the way to Revenge of the Sith in 2005. The cumulative effect of listening to George say one thing and then seem to contradict himself down the line, regarding what was planned and when gives way to the portrait of a frustrated storyteller hoping to be understood. These moments are interspersed with monologues from his production teams, including Empire Strikes Back director, his mentor Irvin Kirshner, Empire and Jedi writer Lawrence Kasdan, FX master craftsman Dennis Muren, animation director Rob Coleman, producer Rick McCallum, concept artist Ralph McQuarrie and the irreplaceable Carrie Fisher.

Rob Coleman, vice president of sales for Holland America Line, talks with Alan Fine of Insider Travel Report about the cruise line's legendary voyages, emphasizing unique routes, such as a full Mediterranean sailing from New York and a pole-to-pole world cruise, with fresh fish to table in 48 hours or less. Coleman also discusses the commissions to be made with group sales through Holland America's Group Advantage program. For more information, visit www.HollandAmerica.com. If interested, the original video of this podcast can be found on the Insider Travel Report Youtube channel or by searching for the podcast's title on Youtube.

In this bonus episode of the EMJ Podcast, host Brigitte Scott is joined by Ketta Lorusso, Humanitas University, Milan, Italy; and Rob Coleman, Vaniam Group, Chicago, Illinois, USA, who discuss key developments in endometrial cancer research that were presented in 2023. This podcast was funded by a medical educational grant from GSK, with the purpose of enhancing the fundamental understanding of oncology specialists of key data and the latest advancements in endometrial cancer care. This content is not intended for US Healthcare Professionals.

On this week's show we report from the Dairygold Tillage Conference. We chat to Bank of Ireland's head of agriculture Eoin Lowry on tillage farmer's finances and changes in markets over time. We have a chat with Cork farmer Rob Coleman about regenerative agriculture and Dairygold's Liam O'Flaherty on beans price and Irish animal feed. We have an update on the seed shortage and take a look at the Department's recommended lists for wheat, oats and beans. As always, we have the grain market and weather reports.

Continuing with our International series I had a great chat with Irish farmer Rob Coleman on farm production, rotations prices, rebates and regulations.

Farming In Ireland can often feel like a gamble, with external factors like Brexit, the pandemic and the war in Ukraine often impacting a producer's bottom line. Speaking to Ciaran Hancock on this week's Inside Business, Rob Coleman, a tillage farmer in North Cork, and Shane McAuliffe, a pig farmer based in Kerry, point out that it's not just the weather forecast that influences their decisions with input costs proving extremely expensive over the last 18 months.Another challenge that Rob and Shane are doing their utmost to meet, is that of climate change. They explain how policy must match individual efforts if the targets for carbon emissions reductions are to be achieved. Hosted on Acast. See acast.com/privacy for more information.

Farming In Ireland can often feel like a gamble, with external factors like Brexit, the pandemic and the war in Ukraine often impacting a producer's bottom line. Speaking to Ciaran Hancock on this week's Inside Business, Rob Coleman, a tillage farmer in North Cork, and Shane McAuliffe, a pig farmer based in Kerry, point out that it's not just the weather forecast that influences their decisions with input costs proving extremely expensive over the last 18 months.Another challenge that Rob and Shane are doing their utmost to meet, is that of climate change. They explain how policy must match individual efforts if the targets for carbon emissions reductions are to be achieved. Hosted on Acast. See acast.com/privacy for more information.

Welcome to the travel industry's new favorite sport: Pickleball. Among our topics this week: How fast this sport has grown among travel companies, why travelers love to play and where travelers and advisors can find creative and plentiful courts and opportunities for play.  Hotels editor Christina Jelski, who spearheaded our May 2023 cover story on pickleball travel and who has tracked the rising popularity of the game within the hospitality sector, co-hosts this episode with host Rebecca Tobin; Melinda Alcossar, a travel advisor who founded Travel With Heart, a division of All-Travel, and specializes in organizing “Carpe Dinkem” pickleball vacations; and Rob Coleman, Holland America Line's vice president of North America sales, which is going “all in” on pickleball. This episode is part of our summer series featuring some of our most memorable recent episodes. This episode was originally published May 15 and has been edited for length and clarity. Episode sponsor This episode is sponsored by ALG Vacations https://www.algvacations.com Related links Cover story: Picking up on the pickleball craze https://www.travelweekly.com/Travel-News/Travel-Agent-Issues/Picking-up-on-the-pickleball-craze Cruise insight: Pickleball is a hit, and Holland America Line has taken notice https://www.travelweekly.com/Cruise-Travel/Insights/Holland-America-is-jumping-into-pickleball River cruise insight: River lines put more sports options into play https://www.travelweekly.com/River-Cruising/Insights/River-lines-put-sports-cruise-options-in-play From 2019: Anyone for pickleball? Resorts embrace the booming sport https://www.travelweekly.com/Travel-News/Hotel-News/Anyone-for-pickleball-Resorts-embrace-booming-sportSee omnystudio.com/listener for privacy information.

Welcome to the travel industry's new favorite sport: Pickleball. Hotels from luxury resorts to urban properties are rapidly adding pickleball courts to their grounds, and cruise lines, even river cruises, are netting off courts on their ships. It seems clear from our reporting that travelers are keen to take their paddles anywhere and everywhere to keep up their routine, play with fellow guests or locals, or use the opportunity to learn the game.Hotels editor Christina Jelski, who spearheaded our pickleball cover story and who has tracked the popularity of the game within the hospitality sector, co-hosts this episode with host Rebecca Tobin. Our guests are Melinda Alcossar, a travel advisor who founded Travel With Heart, a division of All-Travel, and specializes in organizing “Carpe Dinkem” pickleball vacations, and Rob Coleman, Holland America Line's vice president of North America sales, which is going “all in” on pickleball. Among our topics: How fast this sport has grown among travel companies, why travelers love to play and where travelers and advisors can find creative and plentiful courts and opportunities for play. Episode sponsor: This episode is sponsored by Windstar Cruises https://www.windstarcruises.com Related reports: Cover story: Picking up on the pickleball craze https://www.travelweekly.com/Travel-News/Travel-Agent-Issues/Picking-up-on-the-pickleball-craze Cruise insight: Pickleball is a hit, and Holland America Line has taken notice https://www.travelweekly.com/Cruise-Travel/Insights/Holland-America-is-jumping-into-pickleball River cruise insight: River lines put more sports options into play https://www.travelweekly.com/River-Cruising/Insights/River-lines-put-sports-cruise-options-in-play From 2019: Anyone for pickleball? Resorts embrace the booming sport https://www.travelweekly.com/Travel-News/Hotel-News/Anyone-for-pickleball-Resorts-embrace-booming-sport  See omnystudio.com/listener for privacy information.

Rob Coleman

Rob Coleman of our sister church, Grace Church Bolton, on how if God is who we say He is, there is so much more to discover. What does it mean that He's everywhere? If we are struggling to hear from Him, does that mean that He doesn't want us to find Him? Rob uses examples from the Bible to illustrate how God does want us to find Him, does love us and does want us to know Him.

Rob Coleman grew up in a family of entrepreneurial scientists and down the street from the Cold Spring Harbor Lab. So it was a pretty straightforward path for Rob to go from youthful intern to co-founder and CEO of a synthetic biology company.

Rob Coleman

Guest speaker Rob Coleman of Grace Church Bolton on the big picture – who we are and what God has called us to. We are the hope of the world – even if we don't see ourselves like that sometimes.

Email: mailbox@wstrmedia.com Voicemail: (630) 557-9787 Welcome to Episode 249 of WSTR! This episode's topics include: - Rob Coleman - Animation Director for the Prequel trilogy - Why CGI animation is far more important than we realize - The Galactic Starcruiser teaser gets yeeted into Wild Space - ...and much, much, more! For all your galactic news...

Emily Butler and Rob Coleman sit down to discuss how to make the most of your child's college experience while taking the least out of your pocket. How to connect with us and our guest: Emily's Website: www.butlercollegecounseling.com Connect with a Wealth Coach: Info@FosterVictor.com Instagram: @FosterVictorWealthAdvisors YouTube: www.youtube.com/channel/UCk43zuXIgLTS3vq9Vkx

ILM's Rob Coleman provides insight into high-end Character Animation

ILM's Rob Coleman provides insight into high-end Character Animation

Rob Coleman

Have you ever wanted to hear a man talk about how he crossed the sea on a kayak? No? Well nor did Mr Badger.

Rob Coleman

Rob Coleman

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Robert Coleman to for a summary discussion of the VELIA trial.

Dr. Hayes interviews Dr. Trevor Powles his involvement with translational medicine in the UK and early bisphosphonate. Conflict of Interest: Dr. Powles has not reported any conflicts of interest to ASCO.   TRANSCRIPT The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Welcome to JCO's Cancer Stories-- The Art of Oncology brought to you by the ASCO Podcast Network, a collection of nine programs covering a range of educational and scientific content and offering enriching insight into the role of cancer care. You can find all the shows, including this one, at podcast.asco.org. Welcome to Cancer Stories. I'm Dr. Daniel Hayes. I'm a medical oncologist, and I'm a translational researcher at the University of Michigan Rogel Cancer Center in Ann Arbor. And I'm also the past president of the American Society of Clinical Oncology. Today I am privileged to be your host for a series of podcast interviews with the founders of our field-- today in particular Dr. Trevor Powles. Over the last 40 years, I've been fortunate to have been trained, mentored, and inspired by many of these pioneers. It's my hope that through these conversations all of us can be equally inspired by gaining an appreciation of the courage, the vision, and frankly the scientific understanding that these men and women who established the field of clinical cancer care over the last seven decades. By understanding how we got to the present and what we now consider, quote, "normal," end of quote. I hate using quotes, but in oncology I think we can also imagine our work together towards a better future for our patients and their families during and after cancer treatment. As I've noted today, I'm really honored to have as my guest on this podcast Professor Trevor Powles. He's really generally considered one of the true pioneers in breast oncology. Dr. Powles was raised in London, where he went to medical school. He trained in medicine and surgery at St. Bartholomew's Hospital and associated affiliates, graduating from medical school in 1964. He went on to obtain a PhD at the Institute of Cancer Research. He directed his thesis towards hypoglycemia and bone metastasis. Following his PhD, he then completed specialist training in medical oncology at the Royal Marsden and further pursued training in endocrinology with Professor Philip Bundy, [? who was ?] then Chief of endocrinology at Yale before moving to the UK. Dr. Powles remained at the Royal Marsden hospital during the bulk of his distinguished medical career, first as head of the Marsden breast cancer unit, and ultimately is the founding chairman of the Committee for Clinical Research for the entire Royal Marsden. After he retired-- which again requires [INAUDIBLE]-- at the age of 65, Doctor Powles has served on staff at the Cancer Center at London Parkside. Dr. Powles has authored hundreds of peer reviewed papers. He's mentor of many of the leaders in breast college around the world, which we will discuss in a second. And he's really won too many awards and honors from me to list here, but they include the coveted William McGuire Award presented annually at the San Antonio Breast Cancer Symposium-- and by the way, so have two of his mentees, Professors Mitch Dowsett and Ian Smith. And he's also won the Nancy Brinker Award. Many of you know Miss Brinker founded the Komen for the Cure Foundation. And perhaps what is perplexing to those of us in the colonies, in 2002 he and his twin brother Ray were named Commanders of the Most Excellent Order of the British Empire, or CBE for short-- which of course is one of the highest honors one can obtain in the UK-- for their work in breast in Trevor's case, and haematologic cancers in Ray's case. Trevor, I know that a lot of your work also was done with a variety of other contributors, including Dr. John Kanis, Dr. Eugene McCloskey, and of course Sandy Patterson [? period. ?] You've always been quite generous in pointing out that they had a lot to do with your own contributions, and we appreciate that as well. Dr. Powles, welcome to our program. Thank you very much, and thank you for those kind words. Yeah. Actually, I interviewed someone a few weeks ago, and he said, "Geez, that sounded like my mother wrote that." [LAUGHTER] I have a number of questions for you, and I want to start out-- your research and your background was really in endocrinology of the 1960s. And that was a particularly exciting time for endocrinology with the discovery of the hormones not more than 20 years before that, and then the increasing knowledge of understanding of [? the ?] peptides steroid hormone receptors. What made you veer off from that field into oncology in general and breast cancer specifically? When I was working at the Hammersmith Hospital doing my endocrinology [INAUDIBLE] endocrinology there. And one of the conditions we would be looking at would be hypercalcemia with hyperparathyroidism. And hypercalcemia was occurring very commonly in the breast cancer patients in the oncology and the radiotherapy department. [? And ?] to begin with, we thought this would just be another paraendocrine-type syndrome, and that was the thing that really fired my interest. From there, I then wanted to do my PhD to look more into what was causing the hypercalcemia with breast cancer, and that started the whole path of finding out about bone metastases, what they were doing, how they were causing the hypercalcemia, and the path just continued and continued. Most of your work-- I'm going to get to some of the other things you've done-- has been endocrine therapy, endocrine processes, and the bone metastasis, which is really endocrinology. In the United States about that time, most of the excitement in the 60s was around chemotherapy. Was it difficult for you to stick with the endocrine approach? No, it wasn't really. When I first started, all of in the endocrine treatment was ablative treatment. And I knew that from when I was doing my endocrinology is that the hypophysectomy, adrenalectomy, oophorectomy, those were the early days for chemotherapy at using combination chemotherapy and metastatic disease. [INAUDIBLE] and endocrine therapies were far better treatments from the chemotherapy. And although I was doing chemotherapy because we started with single agents then combination treatments-- and there was a lot of chemotherapy going on at that time at the milestone for haematological cancers, lymphoma, teratomas, et cetera-- I was able to do that, but I really focused on the endocrine side. And coming back to the hypercalcemia, the one thing that really impressed me was when I was originally doing my endocrinology was that rapid response you could get to the hypercalcemia by ablative endocrine therapy for oophorectomy, or adrenalectomy, or hypophysectomy. And that was really the thing that started all of the research I did in bone. It started on my PhD with in vitro work. We set up bone assays, I went to Cambridge to [INAUDIBLE] very famous scientist Cambridge to teach us how to do the bone assays for in vitro bone assays. We also set up the animal model with breast cancer. We were able to show that breast cancers could cause bone breakdown and osteolysis in vitro. We could find that we could block that by using drugs like aspirin, and that got us very interested in cross [? demandings. ?] We could then go into the animal experiments. And when we had a rat model using breast cancer that we knew from our assays caused bone breakdown in vitro, and when we did that in the animals by injecting into the aorta we could get bone metastases [? and ?] soft tissue tumor. When we gave aspirin, we could completely prevent the bone metastases-- quite dramatic experiments. And that was what really fired me into getting into the oncology, getting into the endocrine treatment in oncology because of my background in endocrinology. And that has stayed ever since. So what was the timing there? This is the late 60s? My PhD was 1970 to '73. I was at the Hammersmith from '67 to '69, and then I went to [? Barts ?] to endocrinology, and then I came back and then with Bondy in the Marsden, and then I got on the staff of the Marsden as a senior lecturer in 1975. So what you just described to me sounds like translational science. That word wasn't coined until probably 20 years later. Was it unique where you were to be taking things from the lab straight out to the clinic? And where there obstacles to doing that? No, there weren't. The thing that was good about that was we were doing the laboratory work based on what we'd seen, what I'd seen in the endocrinology with the hypercalcemia and the bone metastases, and responding to endocrine therapy. I then was in the PhD, doing the PhD, and then I was able to translate that into the clinic once I then became a consultant. So the main work I was doing when I was first a consultant, the research work, was actually looking at hypercalcemia bone metastases in patients. We had a surprise because when we took the aspirin into patients, we could see no effect at all even though we'd had very dramatic effects in vitro and in vivo. And it was only when the bisphosphonates came through that we were able to then use those, because at this stage we knew it was working on osteoclasts. And it was only when we started to get the bisphosphonates that we really got into the dimension of first of all, being able to treat the hypercalcemia, then being able to switch off the bone metastases, bone pain, and bone fractures with bisphosphonates. And then take it into the adjuvant, I was then able to take it into the adjuvant scene and set up the first adjuvant bisphosphonate trial. So I'd gone right from in vitro, I continued the path right the way through to clinical work. And then what happened was that if we did the bisphosphonate trial and we got the result of just like that had happened in the rats-- it stopped the development of bone metastases and it stopped the hypercalcemia in the rats, but didn't affect the soft tissue. So in the humans, we had exactly the same result where we were able to reduce bone metastases, not have an impact on soft tissue or other disease, and improve mortality. And so we've gone right the way through. It's a story that's extraordinary from my point of view, because I was able to follow the whole path all the way through. And you're absolutely right. That is a really good example of translational research where you hang in there until you get the answer. What's the history behind transferring the bisphosphonates from prevention of osteoporosis in cancer? Now they're widely used as well as denosumab. In fact, it's malpractice not to use them in a patient with bone metastasis. How did you make that leap where you're standing next to somebody who was treating osteoporosis, and you said, "I wonder if that should work?" And how did you get hold of the drug? There's got to be a history behind it. Well, we were looking. We were looking for [? anti-osteodiscitis ?] agents [INAUDIBLE] the aspirin didn't work but [INAUDIBLE] worked so we knew for no reasons at all that it would prevent, stop hypercalcemia. And so we were going down that path, and two really important people in the way the path was going. One was Herbie Fleisch, and Herbie Fleisch [? had ?] suddenly produced bisphosphonates. It was a terrific story if anybody was interested in bone, because it was an agent that clearly was working on osteoclasts, and that was the target we were after. We knew at that stage that the cancer cells had to activate osteoclasts in order to cause the bone breakdown and develop in bone. And the second person who was key was Craig Mundie, who again I met. And I went over to the Boston Dental Hospital several times, and I met Craig and the others there, and that was linking up with being able to see the story that they were developing where tumor cells were activating osteoclasts that were then causing bone breakdown that was then producing growth factors to activate the cancer. So it became a really preferential site for bone metastases to develop because of the interaction between the cancer cells and the osteoclasts. So then there's Herbie Fleisch in Switzerland. I had a few skis with him. He was a very good skiier. But the spin off was that bisphosphonates were going to be the thing that we really [INAUDIBLE] to be looking at. And then we tried four different bisphosphonates. Five foot was a guy in Amsterdam who had APD that was actually the forerunner for [INAUDIBLE]. And the one that worked best for us was clodronate, which we got originally from Finland. And we set up the bone trials. We had to go through three stages. We had to-- first of all, before we could use adjuvant, we had to show that it worked in metastatic bone disease. And it did. It reduced what's called skeletal related events-- that's fracture, hypercalcemia, pain-- requirements of radiotherapy. We then did a trial for phase 3 trial of using clodronate for patients who had metastatic disease but who didn't have bone metastases. And we could reduce the risk of them getting bone metastases. And then we had the justification for doing the-- So let me interrupt you for a minute. Now you're about 1983 or '4 I think when that was probably? Is that right? It was-- yes, it would be. With the adjuvant trial, we would have started in '86. I think. That's the window of time. And then in that trial, we didn't get the results from that until I think it was 1997 when we did the first analysis, and that we were able to then show in that randomized-- it was placebo controlled as well-- we were able to show a reduction in bone metastases and improved survival. And then we did a subsequent analysis in 2006. So we've got longer term data. Back then where other bisphosphonate trials were going on, adjuvant bisphosphonate trails going on, and then we had the meta analysis in 2015, Oxford meta analysis, which I was involved with Rob Coleman. And we did the analysis there, which confirmed that we could reduce bone metastases and improve survival with adjuvant bisphosphonates. So the story that starts from a test tube, so to speak. Oh, there's one other very interesting experiment we [INAUDIBLE] that's never been repeated. Right at the beginning, we were able to show that doing co-cultures-- you're reminding me of things now-- doing co-cultures of the bone assay with human breast tumors I'd get from the Marsden while I was at the institute. We'd have fresh human tumors, and we would do a co-culture and some of them could cause the complete breakdown of the bone assay, and others would not have osteoporosis. And we did a follow up of those patients-- it was only about 30 patients, I think-- and we did a follow up of those patients, and those who had the most bone breakdown in vitro [? with ?] [? those ?] patients who were then going to get the bone metastases. That was a real incentive to show that link that we were getting. So we knew something was going on there. And that experiment was going on in 1971. And in 2015 with the meta analysis of bone mets and mortality. So that's a long story. That's the story. Let me say that this entire story reiterates the phrase that, "On the shoulders of giants we all stand." You look at the number of people you've laid out who led to this story, which is still ongoing. It's actually fascinating. I want to return just a minute to your work with endocrine therapy of breast cancer and your work with tamoxifen. But first of all, a lot of young people listen to this. 'Cause I came in the field just as surgical ablation of many of the origins of estrogen was going away. Can you talk about what it was like to take care of the patients who were having hypophysectomies and adrenalectomies and oopherectomies? I recall thinking, "I'm an endocrinologist here. I'm not a medical oncologist," as a first year fellow taking care of Addison's disease and other things. There are two things about ablative endocrine therapy. The first was that the responses could be very dramatic, and it was quite a high response rate. There was something [INAUDIBLE]-- don't forget we weren't basing it on ER. ER came later, and then [INAUDIBLE]. Even not based on ER, we were getting 30% to 40% response rates, particularly in bone. The second thing is the management of the patients. The hypophysectomies were relatively easy, because I'd already got experience of patients who got pituitary failure from my endocrinology, and that's much it easier to manage. But the adrenalectomies are much more difficult because you can get very acute glucocorticoid symptoms if you're not getting cortisol, whereas in hypophysectomies it's a relatively slow process. And they were much more difficult to look after. But the thing that was important about it was the fact that although we were doing it, these patients were getting hypercalcemia [INAUDIBLE]. You could have a patient who was hypercalcemia, you do ablative surgery, within 48 hours the calcium is back to normal. In fact, it will go hypoglycemic sometimes on bone hungry [INAUDIBLE] thing. And from a clinical point of view, it was some of the best responses we ever saw even up to this time. Now one of the things that came out of that was that we had one patient-- I can say a name because he's long since dead and [INAUDIBLE] anyway-- her name was Mrs. Pottinger. It's engraved in my mind forever. And she had bone metastases, and she was not particularly well and also had some heart problem. And she was due to have adrenalectomy, and she wasn't well enough for adrenalectomy. And so what I did is I'd used [INAUDIBLE] when I was at the Hammersmith as part of treating Cushing's disease. And so I'd already knew about medical treatment for-- so I then decided that we would do-- and I think it must have been the first patient. I had to get permission from [INAUDIBLE], and I still got the letter I wrote to the medical director of [INAUDIBLE] then saying could we use [INAUDIBLE]. So what we do is the basis was in order to get her well enough to have her adrenalectomy, and she did exactly the same as she would have done if we'd done adrenalectomy. Within 24 to 48 hours, she's getting better, the pain's going, the calcium's down. So she then refused to have an adrenalectomy. There's no way she is going to have it. She said, "No I'll continue with the [INAUDIBLE]." And she continued on [INAUDIBLE] for over a year before she died. And that started a whole new thing. [? Ian ?] [? Smith ?] was my registrar at the time. And so we decided we'd do a phase 2 trial. We did a Phase 2 trial of [INAUDIBLE] on the understanding we were doing a medical adrenalectomy. And that started the whole story that we were doing using [INAUDIBLE], because a [INAUDIBLE] came over, I had various other people come, and what we found was the story was. It wasn't the medical adrenalectomy by blocking postmenopausal estrogen. And then we went down the pathway of doing various, about three or four different aromatase inhibitors with Mitch doing all of endocrinology. It's a wonderful time. We had Adrian Harris, Charlie [INAUDIBLE]-- [COUGHING]. [INAUDIBLE]. [INTERPOSING VOICES] That's a parade of stars. Were you talking across the Atlantic a lot during that time with Dick [? Stanton, ?] and Angela Brody, and the other two who were also-- Yes. Angela Brody was the one who got us a source for [INAUDIBLE]. That was the phase 2. Charlie led on that on the phase 2. That was Angela getting us to do that and linked him with Mitch. And Dick Stanton, yes it was a lot of collaborative work with Donald MacDonald. And a lot of the endocrinologists I knew. So that was how that whole story rolled. That's an amazing library. Let me take you back now to your childhood. I know you and your identical twin, Ray-- by the way for the listeners, if you Google either Trevor or Ray Powles, you'll see pictures of the two of them standing together. And I challenge you to tell who's who. [LAUGHTER] Anyway-- Well I could. I could tell the difference. Yeah I know you can tell the difference. I know that you were both young boys in London during World War II. Tell me about the experience then, and how your mother moved you. Obviously, we were very young. My father was in the Navy abroad, so my mother was alone and was looking after my older brother David, who was four or five years older than us. And I can remember the bombing. I can remember quite a lot about it, surprisingly. We were evacuated up into the north of England 1943, 1944, something like that. And we were there for I think something like six months. And it was an incredible story. I went back to see-- I hadn't been back-- I went back to see-- I was up in the north of England, and I suddenly thought I'll go over. We were at a place called Stockton. And so I was five when we left-- four, four years old when we left. And I had no idea. I knew it was Stockton, and I knew the name of the house was the Priory, and I had a faint recollection of the door. And then I went up to Stockton, and I found the house we were in. And I knocked on the door, and it was a major-- a colonel-- Colonel Brown and his sister who lived there. And the sister was still alive, and she must have been about 90. [INAUDIBLE]. And she looked at me and she said, "You're one of the twins." [LAUGHTER] So we had a chat. [INTERPOSING VOICES] At the time, did you think of this as being frightening, or was it just a great adventure for a young boy? Yeah, I wasn't unaware of danger. My house was bombed down the road flattened and presumably a lot of people died, but I was unaware of danger as such. We had a shelter-- it's something called a [INAUDIBLE] shelter, I think it was called-- that was half buried with corrugated iron as the top thing. And if the siren went, I can remember that we would have to go out and get into the shelter. And we could hear the V-1s very, very-- I can still remember. You can hear the V-1s coming over. It made a hum-- [HUMMING] --like that. And it's gradually getting louder and louder, and then it would stop, and then it would just fall out of the sky at an angle. It would go down at about 45 degrees. So if you could hear the [? stop ?] overhead, you weren't going to be hit. But if you could hear the [? stop ?] coming towards you, there was a chance you were going to get hit. I can remember that. Everybody was sitting listening to where these bombs were cutting out their engine. So that's one of the things I can remember. And I can remember the V-2. It was a huge bang if one went off. I know that you and Ray both also developed tuberculosis as young boys. What was the background behind that, and how were you treated? Yeah, Ray-- we'd just finished school. And we weren't sure what we were going to do, and Ray had developed [INAUDIBLE], which again didn't mean anything to me. He coughed up a couple of times or [INAUDIBLE] of blood. And the next thing he's carted off and he's got tuberculosis, and he's been taken down to a sanatorium down near the Thames out along the marshes sort of thing. And he's there for six months. And during that six months, I can't see him and everything, and I thought, "Well, you know I'd like to do medicine. I think this is rather a good thing." So what I did, I then applied for medical school and got a place. And then Ray gets better, and he then applies to medical school, and he gets a place as well. The dean said to Ray when he saw it, he said, "Haven't we seen you here before?" And Ray said, "No, it's my twin brother." And he then says, "Did we accept him?" And Ray said, "Yes." And then he said, "Pity." [LAUGHTER] And it was the end of the interview. The next thing, he's in as well. [LAUGHTER] And then I get TB, because it's about an 80% chance you get it if an identical twin's had it. And I was in the hospital for three months. So we were both back a year. I would have been a year ahead of Ray, but in fact then suddenly we're both back a year. And it was quite an interesting year for me, because I only had one subject to do. So I was able to do some reading, things like Darwin and that sort of stuff. And then we just carried on. And you were treated with streptomycin in those days? [INAUDIBLE]. You had 50 grams of strep. Yeah, yeah. Sounds like you used that as a springboard to change the practice of medicine. So in every cloud there's a silver lining. The one thing I want to bring up-- I remember several years ago at one of the San Antonio meetings, and you and Dr. [? Bernie ?] Fisher were the bait. And he did all but call for you to be arrested and locked up because your study was negative, and of course the [? PL1 ?] one was positive. And you very graciously responded to that, "You know, Dr. Fisher, I didn't start this trial up to be negative." [LAUGHTER] That was a great response. My goodness did I not admire him. The reason I did the trial is-- again, this is a funny story. I did a lot of horse riding, as you know. And what I did is after the 1985 first meta analysis, Oxford meta analysis, that was the first one to show that chemotherapy worked for the [INAUDIBLE] and other trials that chemotherapies show the reduction. And it showed that tamoxifen worked. That was the first meeting where I was really convinced that both those were positive effects. Up till then, it was one trial and you couldn't be sure if it was going to be reproduced all the like. And that was the 1985 meta analysis meeting in Oxford. And then I came back home, and I got on my horse, and I rode for a week. I took the horse down to the South Downs. The South Downs is a long, expansive country, and it took me five days, I think it was, of riding to get across from one side to the other where I'd stop in a pub. I had to go down the week before and plan out exactly what I was going to do. So I've got five days on a horseback thinking, and that was where I thought, "Well, where do we go from here?" You might say, well, let's do bigger and better chemo or the like, right? And you might say endocrine therapy, let's do more tamoxifen, or different doses, or [INAUDIBLE] down those paths. So I said, "But if you really want to do something different, the two things you could do would be for chemotherapy is why not give it before surgery?" That was the time when I really thought neoadjuvant chemotherapy was where we ought to be going, because then we could see that they're responding or not et cetera. But tamoxifen, if it weren't for adjuvant therapy, then it should work for prevention. We had a clinic at the Marsden that I took over because somebody was leaving-- which was a family history clinic, and they all had very strong family histories three or four relatives, et cetera, et cetera. And I took over this clinic, and I thought to myself we could do a prevention trial here with tamoxifen. We'll do a pilot. What happened at the Marsden they just had a ethics committee set up, one of the first in the world. This is in 1985. And it had never met, it had only passed the trials to be done. And so the first meeting of the ethics committee at the Marsden was to discuss the prevention, because it was such a awful thing to do. Do you know what I mean? And but after two or three goes, I got it through the ethics committee mainly because a colleague of mine who was the head of medicine then was Tim McIlwain. He pushed it through because he said "Look, it makes so much sense." And we did a [INAUDIBLE] and we had an agreement that we could do 250 patients randomized, then go to 500. And then we had a national meeting to discuss setting up the national program. And so it was a feasibility trial actually looking to see what the toxicity was or whether it was acceptable to do it. And we had such a spin off from that, because tamoxifen at that stage was supposed to be a pure anti estrogen. And we were screening all the tissues, we were doing bones that [INAUDIBLE] from the clotting factors. Everything. Cholesterol. We were doing, measuring everything in pre and post menopausal women. And everywhere we looked, tamoxifen wasn't acting as an anti estrogen. It was acting as an estrogen effect, so much so that at the Think Tank-- I presented it at the Think Tank, and I said, "Look these aren't [INAUDIBLE] tamoxifen and anti estrogen at all." And I thought Mark, dear old Mark Lippert, was going to have an epilepsy, which 'cause it's correct because it is an anti estrogen breast cancer effect. But that was the first time. So then in the paper I wrote, I called it a selective anti estrogen. But I didn't coin [INAUDIBLE], but I did coin the expression, the first published thing of a selective anti estrogen. I remember that paper. [INAUDIBLE]. I remember that. So I want to finish up with just-- Let me just finish up one thing. Can I just finish up one thing? [INTERPOSING VOICES] Because it links into [INAUDIBLE]. So after Think Tank presented it possibly as an estrogen. And what was happening is we've got a bell shaped curve that was very narrow. So we were on the estrogen side as opposed to the anti estrogen side, right? And that was what was happening in the normal tissues. So I had a slides that said, "Tamoxifen is not an anti estrogen." You probably remember if you were there. You were there. We go out on the boat, and we get stranded out of the boat in the mist-- the one you've mentioned about where you and I and Mark, et cetera-- when we're approaching the time after about four hours when we're thinking about meeting our maker, Mark says to me, "I've really got to have a word with you about this anti estrogen." Well one other thing-- and this is going to be more my talking than yours. I really just touched on the surface of your contributions to the field, but I think probably the greatest is your mentoring history. And you've already hit on a few of these, but I travel extensively and I'm struck by the number of times I've been in some remote area-- or at least remote to me-- and corner of the world, and somebody-- it's usually my host-- volunteers that he or she trained at the Royal Marsden with Trevor Powles. And I think it's one of the things you should be most proud of all the many things you've done. And I want to know that you set up a system that was opening and inviting and also somehow funded to support people to come from all over the world. What made you do that? How did you do that in the first place? It's hard to do. Certain people came to me, which was very nice. We did have funds. I would be able to get funding even at that stage. There are many more hurdles for getting funding now than there were then. And the other thing about it was the fact that I find that people-- many times we've [INAUDIBLE] [? mentioning ?] things-- but one of the things I really did [? let ?] is let people have the run of doing things as opposed to me doing it maybe with the assistant. And that was very rewarding for me in terms of results and [INAUDIBLE], 'cause people were very motivated to do it, people like you, and Charlie, and the others. So in some senses, I think it was the fact I was looking for the results we wanted to get rather than anything else. That's probably the basis of it, and therefore people came who ere good. And I'm very lucky I had very, very good people come. So just to go through the list briefly-- Ian Smith, Mitch Dowsett, Troy [? Kohns, ?] Adrian Harris, Paul Goss, who am I leaving out? Anyway, it's a who's who of breast cancer, especially endocrinology and breast cancer. And they all came out of your brilliance. So we owe you not just for what you've done, but who you've trained to do even more. Very kind of you to say that, but in fact they get the credit because if you look through my publication lists you can see.     Actually, I left out Steven Johnston, of course, who is-- Steve. Yeah, Steve. Yeah. OK, we've run out of time. I very much appreciate the fact that you've taken time to come on and do that for us. I'm sure our listeners will be thrilled by the stories you've told-- at least I always am-- and it's great to hear most of them again. And I hope sometime we can even do this again. So thank you for all you've done, thank you for all the people you've trained, and thank you for taking time to do this today. Well, thank you so much for asking me.   Until next time, thank you for listening to this JCO's Cancer Story-- The Art of Oncology podcast. If you enjoyed what you heard today, don't forget to give us a rating or review on Apple Podcasts or wherever you listen. While you're there, be sure to subscribe so you never miss an episode. JCO's Cancer Stories-- The Art of Oncology podcast is just one of ASCO's many podcasts. You can find all the shows at podcast.asco.org.

This episode is with the incredible Rob Coleman! We talk about working for the National Film Board of Canada, moving to California to work at ILM in '93, what an animation director does, his work on Star Wars, Peter Rabbit, Men in Black, The Lego Movie and so much more! Enjoy! Follow Rob on Twitter at @ArfKeldo

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Robert Soslow for a summary discussion PAOLA trial.

This episode is with the great Ahmed Best! We talk about how growing up in NY influenced his creativity, following through with your ideas, his time on Stomp, pioneering MoCap technology with ILM, brainstorming with Rob Coleman, Liam Neeson putting him on the spot and much more! Enjoy! Follow Ahmed! Twitter: @ahmedbest Instagram: @bestahmed Check out Ahmed's podcast at: http://www.theafrofuturistpodcast.com If you'd like a custom video by Ahmed, with proceeds going to his One Man Show, you can get one at: https://www.cameo.com/ahmedbest?cc=1 (If you like to support The Interesting Podcast and get more exclusive shows, you can do that at Patreon.com/JediBrian)

Rob Coleman is the Director of Business Development at Hennessy Digital.On This Episode We Discuss..- The Main Red Flags of Modern Digital Marketing Agencies- The Habits of Ethical Marketing Agencies- The Tactics Effective Agencies Are Using Today

Happy New Year everyone and welcome to our first episode of 2020! Joining us this week is Rob Coleman from 7 Pot Club and like myself, Rob has a passion for chillies and has loved hot food from a young age. In this episode you'll learn about how Rob's passion for chillies began, the variety of chillies he grows in his front yard and how he preserves chillies and makes his own chilli sauces. Learn more about Rob and 7 Pot Club by visiting: Website: 7pot.club YouTube: 7 Pot Club Facebook: @7PotClub Instagram: @7potclub Twitter: @7potclub

Comedian Rob Coleman joins the Fat Woke Boyz to discuss his hatred of walk away Democrats.  Find out the arguments that get our goat and ruin friendships, plus a short discussion on why universal health care is possible.  Lots of inflammatory statements this week, but some people just deserve to burn.  Recorded by Mike Calhoun.  Produced by Paul Wolfe. #Cleveland #StandUp #Left #Liberal #StayTogetherForTheSakeOfTheKids #Politics #SouthernStrategy #PartyOfLincoln

Rob and Helen Coleman share their powerful stories of God’s grace working in their lives, and how in turn He can work in your life too. The post Our Story of God’s grace / Rob Coleman appeared first on Jubilee Church Wirral.

The show is recorded live, backstage at ROFL (Rolling On the Floor Laughing), the ONLY dedicated Comedy Club in Staffordshire and Cheshire, UK. In this episode hosts Cokey and Franki Falkow talk to Tom Little about how dolphins and wolves are related and lucky underpants.  Tom Little is an award-winning comedian. He once won the Leicester Mercury Comedian of the Year, an award previously won by acts including Johnny Vegas, Rhod Gilbert and Jason Manford, and never stopped going on about it. His last Edinburgh show was nominated for the Amused Moose Comedy Award 2018 and he was also a BBC Radio New Comedy Award finalist. He never shuts up about that either. To connect with Tom visit: Tom's Facebook (http://www.facebook.com/thisistomlittle) Tom's Instagram (https://www.instagram.com/thisistomlittle/) Tom's Twitter (https://twitter.com/ThisIsTomLittle) Cokey and Franki also chat to comic legend and Filmmaker Dave Fulton about Aunt Jemima and Jack Daniels as well as racism, motorcycles and literature.   Dave started making a living doing stand-up comedy stateside back when there was only clubs and Letterman. He certainly never envisioned it would lead to living in London England and to have done shows in 25 different countries. When nothing else is going on he’s building motorcycles, climbing frozen waterfalls and looking after his adopted son. To connect with Dave go to: Dave's Twitter (https://twitter.com/fulton_dave) Dave's website (http://davidfulton.com/) Rob Coleman recently returned from an epic voyage and he touches on his rowing trip across the ocean as well as near death experiences, comedy and dealing with people in close quarters.  Away from comedy Rob is a writer, cyclist, ocean rower and fitness fanatic. He's also done a little acting. To connect with Rob check out: Rob's Website (http://www.robcolemancomedy.co.uk/) Rob's Twitter (https://twitter.com/RobColeman100) Heads Together and Row Facebook Group (https://m.facebook.com/HeadsTogetherandRow/) Hosted by resident MC Cokey Falkow and his wife, writer Franki Falkow, ROFL’s Podcast is one where the comedians enjoy an off-the-cuff backstage chat where no subject is off limits.  Make sure to SUBSCRIBE on your favourite podcast app so you don’t miss out on new episodes. Also check out the ROFL YouTube channel (https://www.youtube.com/channel/UCHnJwtaQWRAGh9WseXsEF3Q) for weekly clips from all the comedians. ROFL brings you the best live comedy every Friday & Saturday night to Lymelight Boulevard at ROFL Comedy Club. For more information and to book tickets go to:  roflcomedy.com (http://www.roflcomedy.com/)

Sunday, 3 November 2019 | Ephesians 6:12 // Rob Coleman | Knowing and Living in our Authority in Christ // Ephesians 6:12 – our struggle isn’t against flesh and blood. // // Notes: // 1. We are God’s workmanship // 2. God created humans to rule and reign over creation, serving in love // 3. He gives us the keys to bind and loose // 4. So let’s take back the ground that the enemy has stolen

Naro Video is closing, but everyone involved wants the video collection to remain intact and available to the public. WHRV's Gina Gambony spoke with owner Tim Cooper, manager Patrick Taylor, treasurer Rob Coleman, and board member Skye Zentz.

I love the Global Golf Post. I read it every chance I get. The photos are tops, the content is well written, and the stories are timely. That's where Rob Coleman comes in. Rob is the Director of Communications and Marketing for Global Golf Post, and has been working on this cutting edge publication for over 5 years. On this episode of the #WednesdayMatchPlay presented y Eat Sleep Golf, we will learn more about his position, where they get content, including the photos, and what the future of this digital publication looks like. This episode of the #WednesdayMatchPlay is presented by Eat Sleep Golf.

Today we have sound problems! We had some major technical/microphone difficulties this week, so the sound quality is similar to that of an old school "Speak and Spell". But, if you bear with us, you'll hear a delightful conversation with the hosts of "All the Time We Have" (Jonathan Bacon-Liu, Kevin Flessing, and Rob Coleman) as we talk all about "Winter Madness" (S4E11). We'll talk about Tracy really getting into America's history, Jenna learning some German words, and we try to keep the Boston accents to a minimum. Make sure to subscribe and listen to "All the Time We Have"! We promise next week's sound quality will be back to normal!tl;drEpisode: "Winter Madness" //Season 4, Episode 11Guest: Jonathan Bacon-Liu, Kevin Flessing, Ron Colemand from "All the Time We Have" (@allthetimepod)Episode Discussion Starts: Around 18:30 See acast.com/privacy for privacy and opt-out information.

Prof Coleman speaks with ecancertv at the 2016 BACR and ECMC Joint Meeting about bone-targeted agents that have links to reducing breast cancer incidence. He describes results from trials of bisphosphonate and denosumab, a well tolerated antibody which inhibits RANK ligand pathways. Prof Coleman also relates the ongoing IBIS III study of bisphosphonates to reduce recurrence and relapse of breast cancer, and considers the future of chemoprevention in health care.

Joining Griffin and David this week is host of the George Lucas Talk Show, Connor Ratliff, to discuss the commentary special feature included with the initial DVD release of the Phantom Menace. Together they review what members of the production crew (including director George Lucas, producer Rick McCallum, sound designer Ben Burtt, animation director Rob Coleman and more) have to say about the filming of this movie and discover new evidence of what went wrong. Do we agree Phantom is like the act one of a play or should the focus have been on making a better stand alone movie? Why is revealing that 85% of the dialogue had to be ADR or reshooting 45 more minutes of footage a year later after principal photography not embarrassing? Could Phantom hold up as a silent film? Also, Griffin talks merch where he spotlights Pepsi collectable soda cans and the golden Yoda, Connor’s fake Phantom Menace rumors that make it to Spin magazine and what is the best joke in the film.

Rob Coleman from Bolton Family Church talks to us about two New Testament servants, Mark and Demas.

Rob Coleman has worked in computer graphics and animation since 1985. He has experienced the use of technology change dramatically over the past 20 years and is very excited about the future of digital filmmaking. Coleman discusses the use of technology in today’s animation production pipeline as well as the many tools that will be available to artists and filmmakers in the near future.Coleman is Animation Director at Lucasfilm Animation in Marin County, California. He is currently working on an animated television series and is developing an animated feature film.